Paper Details

  1. Home
  2. Paper Details

The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.

Author: DanielDavid G, HarriganEdmund P, SwiftRachel H, ZimbroffDan L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Intramuscular ziprasidone is a well-tolerated alternative to conventional intramuscular agents for managing agitated patients with psychosis. In a 7-day study, ziprasidone (5-20 mg qid) was associated with fewer movement disorders compared to haloperidol (up to 10 mg bid-qid). Both treatments effectively controlled symptoms and transitioned well to oral medication.
Paper Details　
Original Abstract of the Article :
The intramuscular (i.m.) formulation of ziprasidone offers promise as an alternative to conventional i.m. agents for the short-term management of agitated patients with psychosis. This 7-day, randomized, open-label study evaluated the tolerability of ziprasidone i.m. and haloperidol i.m. in hospital...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00004850-200401000-00002

データ提供：米国国立医学図書館（NLM）

Ziprasidone: A Promising Treatment for Agitation in Psychosis

Psychosis can be a challenging condition, often leading to agitation and distress. This study evaluated the effectiveness and safety of ziprasidone, a medication used to treat psychosis, in hospitalized patients experiencing agitation. It’s like finding a calming oasis in the midst of a mental desert.

The researchers compared ziprasidone to haloperidol, a more traditional antipsychotic medication. They found that ziprasidone, like a cool breeze in the desert, was well tolerated and effectively controlled agitation, with fewer movement disorders than haloperidol.

The Advantages of Ziprasidone

This study highlights the potential benefits of ziprasidone for treating agitation in psychosis. It’s like discovering a more comfortable camel saddle – offering a smoother and more effective ride. This discovery could lead to improved treatment outcomes for patients with psychosis.

Implications for Mental Health Treatment

This research is encouraging, but further studies are needed to confirm the long-term safety and effectiveness of ziprasidone. It’s like carefully mapping a new route through the desert – ensuring its reliability before making it a standard path. We need to continue to explore the possibilities of this medication and find the best ways to use it to help patients with psychosis.

Dr. Camel's Conclusion

The desert of mental health research is vast and challenging. This study offers a glimpse into a promising new treatment option. It’s like a guiding beacon in the desert, leading us toward a better future for patients with psychosis. This journey requires dedication and compassion, but with each new discovery, we inch closer to finding a cure.

Date :
  1. Date Completed 2004-05-25
  2. Date Revised 2019-10-26
Further Info :

Pubmed ID

15101564

DOI: Digital Object Identifier

10.1097/00004850-200401000-00002

Related Literature

Article Analysis
・Effects of ziprasidone injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.